VTGN

2.39

0.00% 0.00

Dopo l'orario di chiusura: 2.36 -0.03 -1.26%

Vistagen Therapeutics Inc (VTGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.39

Aprire:

$2.39

Volume 24 ore:

47,216

Relative Volume:

0.37

Capitalizzazione di mercato:

$68.98M

Reddito:

$875.70K

Utile/perdita netta:

$-39.57M

Rapporto P/E:

-1.7805

EPS:

-1.3423

Flusso di cassa netto:

$-33.65M

1 W Prestazione:

-5.53%

1M Prestazione:

+0.63%

6M Prestazione:

-8.78%

1 anno Prestazione:

-39.34%

Intervallo 1D:

$2.34

$2.415

Intervallo di 1 settimana:

$2.31

$2.63

Portata 52W:

$1.90

$4.21

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Nome

Vistagen Therapeutics Inc

Settore

Healthcare (1170)

Industria

Biotechnology (665)

Telefono

650-577-3600

Indirizzo

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Dipendente

Cinguettio

@vistagen

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

VTGN's Discussions on Twitter

Confronta VTGN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTGN Vistagen Therapeutics Inc	2.39	73.02M	875.70K	-39.57M	-33.65M	-1.3423
ONC Beone Medicines Ltd Adr	258.27	26.01B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.85	114.30B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.3499	41.83M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	83.98	6.29B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	484.93	63.90B	14.09B	4.50B	2.96B	39.28

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-07	Aggiornamento	Jefferies	Hold → Buy
2023-08-07	Aggiornamento	Maxim Group	Hold → Buy
2022-07-22	Downgrade	Jefferies	Buy → Hold
2022-07-22	Downgrade	Robert W. Baird	Outperform → Neutral
2022-07-22	Downgrade	William Blair	Outperform → Mkt Perform
2021-05-20	Iniziato	Robert W. Baird	Outperform
2021-02-18	Iniziato	Jefferies	Buy
2021-01-04	Aggiornamento	William Blair	Mkt Perform → Outperform
2018-06-27	Iniziato	Maxim Group	Buy
2018-02-08	Reiterato	Chardan Capital Markets	Buy
2017-03-28	Iniziato	Maxim Group	Buy

Mostra tutto

Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie

Jun 04, 2025

Vistagen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Jun 04, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World

Jun 04, 2025

Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa

Jun 03, 2025

Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - marketscreener.com

Jun 02, 2025

Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan

Jun 02, 2025

May 31, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat

May 31, 2025

May 28, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise

May 28, 2025

Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 23, 2025

Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan

May 23, 2025

May 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat

May 11, 2025

May 08, 2025

254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat

May 08, 2025

May 06, 2025

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

May 06, 2025

May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025

May 04, 2025

Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

May 04, 2025

Apr 29, 2025

JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Apr 29, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 24, 2025

JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Apr 24, 2025

Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace

Apr 17, 2025

Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Apr 06, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World

Apr 06, 2025

Apr 04, 2025

VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK

Apr 04, 2025

Apr 03, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Apr 03, 2025

Mental Disorder Treatment Market Set to Witness Significant - openPR.com

Apr 03, 2025

Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com

Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025

Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025

Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025

Mar 12, 2025